H1 2023 Financial Highlights

Sales performance Growth platforms continuing to excel; contributions from newly acquired medicines IPSEN Innovation for patient care H1 2023 Q2 2023 €m change €m change Dysport Decapeptyl 319 31.7% 165 38.3% 277 6.0% 147 11.0% Cabometyx 266 26.3% 135 22.1% Onivyde 78 -8.0% 41 -3.7% Growth platforms 940 17.7% 488 20.6% Bylvay 23 n/a 18 n/a Tazverik 19 n/a 9 n/a Newly acquired medicines 42 n/a 28 n/a Somatuline 529 -12.0% 266 -14.1% Other 27 -15.2% 14 -9.8% Total sales 1,537 7.4% 795 9.0% All growth rates are at constant exchange rates. Due to rounding, the sum of euro values may not agree to totals. 7

View entire presentation